Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Change in Cash: 2021-2025

Historic Change in Cash for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$1.7 million.

  • InMed Pharmaceuticals' Change in Cash fell 76.50% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 424.43%. This contributed to the annual value of $4.5 million for FY2025, which is 292.42% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its Change in Cash stood at -$1.7 million for Q3 2025, which was down 127.28% from $6.4 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Change in Cash ranged from a high of $8.0 million in Q3 2021 and a low of -$5.4 million during Q1 2022.
  • In the last 3 years, InMed Pharmaceuticals' Change in Cash had a median value of -$1.0 million in 2024 and averaged -$192,864.
  • In the last 5 years, InMed Pharmaceuticals' Change in Cash slumped by 348.26% in 2023 and then surged by 721.59% in 2025.
  • Quarterly analysis of 5 years shows InMed Pharmaceuticals' Change in Cash stood at -$4.1 million in 2021, then soared by 151.73% to $2.1 million in 2022, then surged by 33.04% to $2.8 million in 2023, then plummeted by 177.37% to -$2.2 million in 2024, then crashed by 76.50% to -$1.7 million in 2025.
  • Its last three reported values are -$1.7 million in Q3 2025, $6.4 million for Q2 2025, and $1.3 million during Q1 2025.